<DOC>
	<DOCNO>NCT01046058</DOCNO>
	<brief_summary>The purpose study investigate effect moderate severe hepatic impairment pharmacokinetics TMC435 . Pharmacokinetics mean drug absorb bloodstream , distribute body eliminate body . In addition , short-term safety tolerability TMC435 participant hepatic impairment determine . The result study guide dose recommendation TMC435 patient impaired liver function .</brief_summary>
	<brief_title>TMC435-TiDP16-C113 : A Study Investigate Effect Hepatic Impairment Pharmacokinetics TMC435</brief_title>
	<detailed_description>This Phase I , open-label trial investigate pharmacokinetics ( drug absorb bloodstream , distribute body eliminate body ) TMC435 8 participant moderate hepatic impairment 8 participant severe hepatic impairment compare 8 participant normal hepatic function , match age , gender , race , BMI ( body mass index = weight kilogram divide square height meter ) smoking status . Open-label mean study doctor participant know treatment assign . All participant receive 150 mg TMC435 mouth 7 day . Participants severe hepatic impairment treat pharmacokinetic profile TMC435 participant moderate hepatic impairment evaluate . The dose TMC435 may change participant severe hepatic impairment evaluation blood level TMC435 participant moderately impaired hepatic function . Tolerability safety TMC435 assess throughout trial period . Illnesses side effect check every visit . Blood sample take screening , day TMC435 intake , day 2 , 3 , 5 , 6 , 7 ( 11 time ) , 8 9 2 follow-up visit . Blood level TMC435 determine day 2 , 5 , 6 , 7 , 8 9 . Urine sample , ECG vital sign take screening , twice day 7 2 follow-up visit . A physical examination do screening , day TMC435 intake , day 9 follow-up visit . All participant receive 150 mg dose TMC435 7 day , give mouth 2 capsule 75 mg. After evaluation pharmacokinetic profile TMC435 participant moderate hepatic impairment , dose may change participant severe hepatic impairment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Participants hepatic impairment : Moderate severe hepatic impairment , clinically diagnose Child Pugh B C Stable liver cirrhosis hepatic impairment least 3 month prior start study . Participants normal hepatic function : Healthy base medical evaluation include medical history , physical examination , blood test electrocardiogram Participants hepatic impairment : Fluctuating rapidly deteriorate hepatic function indicate widely vary worsen clinical and/or laboratory sign hepatic impairment within 3 month prior within screen period Cirrhosis due chronic hepatitis B C infection . Participants normal hepatic function : History presence hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>TMC435-TiDP16-C113</keyword>
	<keyword>TMC435-C113</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>